# ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

> **NCT02616497** · PHASE4 · COMPLETED · sponsor: **University of Ioannina** · enrollment: 1220 (actual)

## Conditions studied

- Atherothrombosis

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Triflusal

## Key facts

- **NCT ID:** NCT02616497
- **Lead sponsor:** University of Ioannina
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-02-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 1220 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616497, "ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02616497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*